JAX-NYSCF and GSK Partner to Advance Translational Models for Neurodegenerative Diseases
Wednesday, February 18, 2026
The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) has entered into a five-year strategic research collaboration with GSK to advance human cellular models for neurodegenerative diseases, including Alzheimer’s disease.
The partnership aims to strengthen translational research by combining human stem cell science, advanced data tools and large-scale research systems. The objective is to develop disease-relevant cellular models that improve understanding of the underlying biology of conditions such as Alzheimer’s disease and support the development of new therapies.
The collaboration follows JAX’s recent expansion of its discovery platform through the acquisition of the New York Stem Cell Foundation (NYSCF). By integrating traditional disease models with next-generation patient-derived induced pluripotent stem cell (iPSC) models, the partners intend to create systems that more accurately reflect the complexity of human biology.
Through this agreement, GSK will contribute its expertise in neurodegeneration, translational science and drug discovery. JAX-NYSCF will provide stem cell technologies, access to relevant patient cohorts and its automation platform. Together, the organisations plan to develop more predictive models to help identify and prioritise potential drug candidates.
The collaboration is expected to enhance early-stage discovery efforts and accelerate progress towards new treatment options for neurodegenerative diseases.
Source: prnewswire.com
